uroxatral

Uroxatral

Product dosage: 10mg
Package (num)	Per pill	Price	Buy
30	$1.74	$52.18 (0%)	🛒 Add to cart
60	$1.42	$104.35 $85.29 (18%)	🛒 Add to cart
90	$1.32	$156.53 $118.40 (24%)	🛒 Add to cart
120	$1.20	$208.71 $144.49 (31%)	🛒 Add to cart
180	$1.10	$313.06 $198.67 (37%)	🛒 Add to cart
270	$1.00	$469.59 $270.92 (42%)	🛒 Add to cart
360	$0.90 Best per pill	$626.12 $325.10 (48%)	🛒 Add to cart
Synonyms Alfuzosin

Show more

Uroxatral, known generically as alfuzosin, is an alpha-1 adrenergic receptor antagonist specifically indicated for the symptomatic treatment of benign prostatic hyperplasia (BPH). Unlike non-selective alpha-blockers, its uroselective profile targets receptors in the prostate and urethra with reduced effects on blood pressure, making it a cornerstone in BPH management. This monograph provides a comprehensive, evidence-based review of its pharmacology, clinical applications, and practical considerations.

1. Introduction: What is Uroxatral? Its Role in Modern Medicine

Uroxatral is the brand name for the prescription medication alfuzosin hydrochloride, classified as an alpha-1 blocker. Its primary role in modern urology is the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. When the prostate enlarges, it constricts the urethra, causing obstructive and irritative symptoms like weak stream, hesitancy, nocturia, and urgency. Uroxatral works by relaxing smooth muscle in the prostate neck and bladder, effectively reducing dynamic obstruction. Its development represented a significant advance over earlier alpha-blockers by offering improved uroselectivity, thereby minimizing cardiovascular side effects like significant hypotension. For millions of men, Uroxatral provides a first-line pharmacological option to improve quality of life without immediate recourse to surgery.

2. Key Components and Bioavailability of Uroxatral

The active pharmaceutical ingredient in Uroxatral is alfuzosin hydrochloride. It is formulated as an extended-release (ER) tablet, typically in 10 mg strength. The critical innovation of the Uroxatral formulation is its unique extended-release delivery system, which utilizes a hydrophilic gel matrix. This system controls the dissolution and absorption of alfuzosin over several hours, maintaining stable plasma concentrations with once-daily dosing. This is crucial because it avoids the sharp peak plasma levels associated with immediate-release formulations, which are linked to a higher incidence of side effects like dizziness and orthostatic hypotension. The bioavailability of alfuzosin from the Uroxatral ER tablet is approximately 49% and is not significantly affected by food, unlike some other alpha-blockers, which provides flexibility in administration for patients.

3. Mechanism of Action of Uroxatral: Scientific Substantiation

The mechanism of action of Uroxatral is rooted in its selective antagonism of post-synaptic alpha-1 adrenergic receptors. It’s important to understand that prostate and urethral smooth muscle tone is partially regulated by the sympathetic nervous system via these receptors. Specifically, Uroxatral has a high affinity for the alpha-1A receptor subtype, which is predominantly located in the prostate, prostatic capsule, prostatic urethra, and bladder neck. By blocking these receptors, Uroxatral inhibits the binding of norepinephrine, a neurotransmitter that causes muscle contraction. Think of it as turning off the “squeeze” signal to the muscles surrounding the urethra. This results in relaxation of these muscles, a decrease in urethral resistance, and a consequent improvement in urine flow rate and a reduction in obstructive symptoms. Its lower affinity for the alpha-1B receptors found in vascular smooth muscle is what confers its relative cardiovascular safety.

4. Indications for Use: What is Uroxatral Effective For?

Uroxatral is specifically indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia.

Uroxatral for Obstructive Urinary Symptoms

This is the primary indication. Clinical trials consistently show that Uroxatral significantly improves peak urinary flow rate (Qmax) and reduces the International Prostate Symptom Score (IPSS). Patients report less straining, a stronger stream, and reduced feeling of incomplete bladder emptying.

Uroxatral for Irritative Urinary Symptoms

While primarily targeting obstruction, the relief provided often ameliorates irritative symptoms as well. This includes a reduction in urinary frequency, urgency, and nocturia (waking up at night to urinate), as the bladder is less overworked and irritated from trying to overcome the obstruction.

It is critical to note that Uroxatral treats the symptoms of BPH; it does not reduce the size of the prostate gland itself (unlike 5-alpha reductase inhibitors) or halt the disease’s progression. It is a management tool for symptom control.

5. Instructions for Use: Dosage and Course of Administration

The standard dosage of Uroxatral is one 10 mg extended-release tablet taken once daily. Adherence to proper administration is vital for efficacy and safety.

• Initiation: Treatment should be initiated and monitored by a physician after a proper diagnosis of BPH.
• Course of Administration: The effects on symptoms can be seen within a few weeks, but the full therapeutic benefit may take up to 4-6 weeks. Treatment is typically long-term for as long as symptomatic relief is desired.
• Missed Dose: If a dose is missed, it should be taken with food as soon as remembered on that same day. Patients should not take a double dose the next day.

6. Contraindications and Drug Interactions with Uroxatral

Patient safety is paramount when prescribing Uroxatral.

Contraindications:

• Hypersensitivity to alfuzosin or any component of the formulation.
• Moderate or severe hepatic impairment (due to altered metabolism).
• Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). This can drastically increase alfuzosin plasma levels and the risk of severe hypotension.
• History of orthostatic hypotension.

Drug Interactions:

• Other Alpha-Blockers: Concurrent use (e.g., with tamsulosin, doxazosin) is contraindicated due to additive effects and increased risk of hypotension.
• Phosphodiesterase-5 Inhibitors: Concomitant use with drugs like sildenafil (Viagra) or tadalafil (Cialis) can potentiate blood pressure-lowering effects and is generally not recommended.
• Antihypertensives: Caution is advised when used with other blood pressure medications (e.g., calcium channel blockers, ACE inhibitors, beta-blockers) as the blood pressure-lowering effects may be amplified.

Special Populations:

• Pregnancy/Lactation: Not indicated for use in women.
• Geriatric: Older patients may be more susceptible to postural hypotension and dizziness.

7. Clinical Studies and Evidence Base for Uroxatral

The efficacy of Uroxatral is supported by numerous randomized, double-blind, placebo-controlled trials. A landmark 12-month study published in the Journal of Urology demonstrated that alfuzosin 10 mg once daily provided a statistically significant and clinically relevant improvement in IPSS compared to placebo, with a mean difference of over 3 points. Peak flow rates (Qmax) improved by an average of 1.5-2.5 mL/s over baseline, a meaningful improvement for patients. The ALF-ONE study program, a large series of trials, further confirmed its sustained efficacy and favorable safety profile over both short-term (3 months) and long-term (up to 3 years) treatment periods. The data consistently shows that while its effect on flow rate is slightly less than some other alpha-blockers, its incidence of cardiovascular side effects, particularly vasodilatory events, is notably lower, reinforcing its uroselective profile.

8. Comparing Uroxatral with Similar Products and Choosing a Quality Product

When comparing Uroxatral to other BPH medications, the choice often hinges on the balance between efficacy, side effect profile, and cost.

• Vs. Tamsulosin (Flomax): Tamsulosin is also highly uroselective. Some meta-analyses suggest a slightly greater improvement in flow rate with tamsulosin, but it carries a risk of a unique side effect: retrograde ejaculation, which is less common with alfuzosin. Uroxatral’s requirement to be taken with food can be a minor inconvenience compared to tamsulosin’s food-independent dosing.
• Vs. Doxazosin & Terazosin: These older, non-selective alpha-blockers are effective but have a much higher incidence of dizziness and orthostatic hypotension due to their significant effects on blood vessels. They often require dose titration.
• Choosing Quality: As a branded prescription product, Uroxatral is subject to strict FDA manufacturing standards. The key for patients is to obtain it from a legitimate pharmacy with a valid prescription. Generic alfuzosin is bioequivalent and provides a cost-effective alternative, but the formulation and extended-release properties must be identical to ensure consistent clinical effect.

9. Frequently Asked Questions (FAQ) about Uroxatral

How quickly does Uroxatral start working?

Some patients may notice an improvement in urinary symptoms within 1-2 weeks, but the full therapeutic effect is typically observed after 4-6 weeks of consistent use.

Can Uroxatral be taken at night?

It can be, as long as it is taken immediately after the same meal each day. If a patient takes it after dinner, this is acceptable. For some patients with significant nocturia, this timing might be beneficial.

Does Uroxatral lower blood pressure?

It can cause a small, usually clinically insignificant, decrease in blood pressure. Significant hypotension is uncommon due to its uroselectivity, but patients should be cautious, especially when starting therapy or rising from a sitting/lying position.

Can Uroxatral be combined with Cialis (tadalafil)?

Concomitant use is not generally recommended due to the potential for additive blood pressure-lowering effects, which could lead to dizziness and fainting. This combination should only be considered under close medical supervision.

10. Conclusion: Validity of Uroxatral Use in Clinical Practice

In conclusion, Uroxatral remains a valid and important therapeutic option in the urologist’s arsenal for managing BPH. Its strong evidence base, demonstrated efficacy in improving both obstructive and irritative urinary symptoms, and favorable safety profile rooted in its uroselectivity make it a reliable first-line treatment. While it does not alter the underlying disease progression, it provides significant symptomatic relief, improving quality of life for countless men. The key to its successful use lies in appropriate patient selection, awareness of contraindications and drug interactions, and patient education on proper administration.

I remember when we first started using alfuzosin in the clinic, there was some skepticism from the older guys who were used to the more potent, but also more side-effect-prone, doxazosin. We had a patient, Robert, 72, with pretty classic moderate BPH—his IPSS was 21, flow rate was dismal. His main complaint was the nocturia, up 4-5 times a night, just wrecking his sleep. He was also on a stable dose of lisinopril for hypertension. We started him on Uroxatral 10 mg after his evening meal. I’ll be honest, the first week he called, a bit frustrated, saying he didn’t feel any different. We urged patience. At the 4-week follow-up, the change was stark. His IPSS dropped to 12. But the thing he was most thrilled about? “Doc, I’m only getting up once, maybe twice a night. I feel human again.” The flow rate improvement was solid, but the impact on his sleep and daily energy was the real win. We did have a case, Mark, a 68-year-old who we later found out was also taking over-the-counter fluconazole for a recurrent nail fungus. He presented with significant dizziness and a near-faint. It was a tough lesson—we’d asked about prescriptions but not OTC meds. That interaction with the CYP3A4 inhibitor was a real-world reminder to dig deeper in the medication history. It’s not a miracle drug, but for the right patient, the quality-of-life improvement with Uroxatral is tangible and sustained. I saw Robert a year later, and he was still doing well, happily reporting he’d even started a morning walking group with his wife. That’s the outcome we’re always aiming for.